Kinin‐generating Cascade in Advanced Cancer Patients and in vitro Study

Japanese Journal of Cancer Research

Volumn 82, Issue 6, 1991, Pages 732-741

  Matsumura, Yasuhiro ^a   Maruo, Keishi ^a   Kimura, Masami ^a   Yamamoto, Tetsuro ^a   Konno, Toshimitsu ^a   Maeda, Hiroshi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Bradykinin; Cancer; Kallikrein; Plasminogen activater; Vascular permeability

Indexed keywords

BRADYKININ; KALLIKREIN; KININ; PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANIMAL; CELL LINE; COMPARATIVE STUDY; FACTOR XII; FEMALE; HUMAN; KALLIKREINS; KININOGENS; MALE; MIDDLE AGE; NEOPLASMS; PREKALLIKREIN; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T;

EID: 0025806374     PISSN: 09105050     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1991.tb01910.x     Document Type: Article

References (55)

1. A lipophilic derivative of neocarzinostatin, A polymer conjugation to an antitumor protein antibiotic
2. Cancer selective macromolecular therapeusis: tailoring of antitumor protein drugs
3. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
4. Tumoritropic and lymphotropic principle of macromolecular drugs
5. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report
6. Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium
7. Use of oily contrast medium for selective drug targeting to tumor enhanced therapeutic effect and X‐ray image
8. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver
9. Involvement of the kinin‐generating cascade in enhanced vascular permeability in tumor tissue
10. 3‐bradykinin in ascitic fluid from a patient with gastric cancer
11. The interrelationship of coagulation of plasma and release of peptides
12. Substrates for plasma kinin‐forming enzymes in human, dog and rabbit plasmas
13. HMW and LMW kininogens
14. Enzymes that inactivate active polypeptides
15. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum; role of carboxypeptidase, angiotensin‐converting enzyme and determination of final degradation products
16. Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC
17. Human factor XII (Hageman factor)
18. Purification of guinea‐pig plasma prekailikrem: activation by prekallikrein activator derived from guinea‐pig skin
19. Plasminogen, the serum proenzyme activated by factors from cells transformed by oncogenic viruses
20. Fluorometric assay for plasma prekallikrein using peptidyl‐methylcoumarinylamide as a substrate
21. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases
22. Enzyme immunoassay of bradykinin using β‐d‐galactosidase as a labelling enzyme
23. 3‐bradykinin using a competitive binding enzyme immunoassay
24. Reaction of fluoresceinisothiocyanate with proteins and amino acids. I. Covalent and non‐covalent binding
25. Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF‐7 and MDA‐MB‐231
26. A spectrophotometric solid‐phase fibrin‐tissue plasminogen activator assay (SOFIA‐tPA) for high‐fibrin‐affinity tissue plasminogen activators
27. J. Protein measurement with the Folin phenol reagent
28. Experimental studies on the uptake and retention of labelled proteins in a rat
29. Induction of a fibrin gel investment: an early event in Line 10 hepatocarcinoma growth mediated by tumor‐secreted products
30. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
31. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury
32. Regulation of extravascular coagulation by microvascular permeability
33. Pepstatin – an inhibitor of leukokinin formation and ascitic fluid accumulation
34. Pathogenic potentials of bacterial proteases
35. Pathogenesis of serratial infection: activation of the Hageman factor‐prekallikrein cascade by serratial protease
36. Plasma kallikrein activation and Hageman factor in Gram‐negative bacteria
37. Activation of the kallikrein‐kinin system in Rocky Mountain spotted fever
38. Content and characterization of plasminogen activators in human lung tissue
39. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue
40. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas
41. Relationship between fibrinolysis of cultured cells and malignancy
42. Plasminogen activator and cancer
43. Relation of vascular proliferation to growth
44. Angiogenesis in vitro
45. Correlation of collagenase secretion with metastatic colonization potential in naturally occurring marine mammary tumors
46. Plasminogen activators, tissue degradation, and cancer
47. Surface‐mediated defence reactions: the plasma contact activation system
48. The coagulation‐kinin pathway of human plasma
49. The contact activation system of plasma: biochemistry and pathophysiology
50. Activation of bovine factor XII (Hageman factor) by plasma kallikrein
51. Comparative study of plasminogen activators in cancers and normal mucosa of human urinary bladder
52. Effects of fibrinogen and fibrin on the activation of Glu‐ and Lysplasminogen by urokinase
53. Fibrino‐genolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase‐activated human globulin, and plasmin
54. Cytological observations on carcinoma
55. Fibrin in human tumors